1. Academic Validation
  2. Fenbendazole as a potential anticancer drug

Fenbendazole as a potential anticancer drug

  • Anticancer Res. 2013 Feb;33(2):355-62.
Qiwen Duan 1 Yanfeng Liu Sara Rockwell
Affiliations

Affiliation

  • 1 Department of Therapeutic Radiology, Yale University School of Medicine, PO Box 208040, New Haven, CT 06520-8040, USA. sara.rockwell@yale.edu
PMID: 23393324
Abstract

Background/aims: To evaluate the Anticancer activity of fenbendazole, a widely used antihelminth with mechanisms of action that overlap with those of the hypoxia-selective nitroheterocyclic cytotoxins/radiosensitizers and the taxanes.

Materials and methods: We used EMT6 mouse mammary tumor cells in Cell Culture and as solid tumors in mice to examine the cytotoxic and antitumor effects of fenbendazole as a single agent and in combination regimens.

Results: Intensive treatments with fenbendazole were toxic to EMT6 cells in vitro; toxicity increased with incubation time and under conditions of severe hypoxia. Fenbendazole did not alter the dose-response curves for radiation or docetaxel; instead, the agents produced additive cytotoxicities. Febendazole in maximally-intensive regimens did not alter the growth of EMT6 tumors, or increase the antineoplastic effects of radiation.

Conclusion: These studies provided no evidence that fenbendazole would have value in Cancer therapy, but suggested that this general class of compounds merits further investigation.

Figures
我们的 Cookie 政策

我们使用 Cookies 和类似技术以提高网站的性能和提升您的浏览体验,部分功能也使用 Cookies 帮助我们更好地理解您的需求,为您提供相关的服务。 如果您有任何关于我们如何处理您个人信息的疑问,请阅读我们的《隐私声明》